LEWIS LUNG-CARCINOMA LINES WITH DIFFERENT METASTATIC BEHAVIOR - RESPONSE TO ICRF-159

  • 1 January 1984
    • journal article
    • research article
    • Vol. 4  (1-2) , 91-95
Abstract
Three [mouse] Lewis lung carcinoma lines (3LL) with different metastatic behavior were investigated with regard to their response to Razoxane (ICRF-159). The effects of different schedules were tested on primary and secondary tumors. The lines are heterogeneous in their response to this antimetastatic agent. In particular, BM21548, the least metastatic line, is also less sensitive to ICRF-159. A better response can be achieved with this line by a proper fractionation regimen which takes into account the delayed metastasis release from primary tumor. As far as M1087 is concerned, the most metastatic line, secondaries are greatly affected by ICRF-159 treatment if performed at a moderately advanced stage of growth. Metastases from early tumor stages can be better controlled by radical surgery of the primary implant than by treatment with ICRF-159.